Get the Stockscreener App
6.96
4.26%
-0.31
After Hours:
6.96
Precision Biosciences Inc stock is traded at $6.96, with a volume of 444.17K.
It is down -4.26% in the last 24 hours and down -11.68% over the past month.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
See More
Previous Close:
$7.27
Open:
$7.31
24h Volume:
444.17K
Relative Volume:
1.67
Market Cap:
$179.61M
Revenue:
$34.26M
Net Income/Loss:
$-46.61M
P/E Ratio:
-1.3435
EPS:
-5.1806
Net Cash Flow:
$-62.01M
1W Performance:
-11.45%
1M Performance:
-11.68%
6M Performance:
+33.33%
1Y Performance:
+47.77%
1-Day Range:
$6.80
$7.63
1-Week Range:
$6.80
$8.59
52-Week Range:
$3.53
$8.82
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
6.96 | 187.61M | 34.26M | -46.61M | -62.01M | -5.1806 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
Precision BioSciences stock (US74019P1084): gene-editing player updates clinical pipeline and strate - AD HOC NEWS
Number of shareholders of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
DTIL Stock Chart | PRECISION BIOSCIENCES INC (NASDAQ:DTIL) - ChartMill
Precision BioSciences (DTIL) Highlights Promising Data in DMD Tr - GuruFocus
Precision Biosciences Presents New Preclinical Data Supporting Advancement of Pbgene-Dmd into Clinic - marketscreener.com
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Cl - PharmiWeb.com
Precision BioSciences (DTIL) Highlights Promising Data in DMD Treatment - GuruFocus
Precision BioSciences presents DMD gene therapy preclinical data - Investing.com
Precision BioSciences presents DMD gene therapy preclinical data By Investing.com - Investing.com Canada
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting - Business Wire
Analyst Forecasts For Precision BioSciences, Inc. (NASDAQ:DTIL) Are Surging Higher - simplywall.st
Bullish: Analysts Just Made A Notable Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts - Yahoo Finance
Precision BioSciences stock (US74019P1084): Q3 2024 earnings report shows EPS loss - AD HOC NEWS
Precision BioSciences exits substantial shareholder role in Imugene - TipRanks
DTIL SEC FilingsPrecision Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Precision BioSciences (DTIL) reports Q1 loss, tops revenue estimates - MSN
Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Nuvectis Pharma (NVCT) - The Globe and Mail
Guggenheim Initiates Precision BioSciences(DTIL.US) With Buy Rating, Announces Target Price $19 - Moomoo
H.C. Wainwright Maintains Precision BioSciences(DTIL.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Precision BioSciences Q1 2026 earnings preview - MSN
Precision BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MSN Money - MSN
DTIL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Precision BioSciences reports Q1 EPS (75c) vs. ($2.21) last year - TipRanks
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Precision BioSciences (DTIL) Q1 2026 loss narrows as gene-editing pipeline advances - Stock Titan
Precision BioSciences 1Q 2026: Revenue $10.8M, EPS $(0.75) — 10-Q Summary - TradingView
Precision BioSciences (DTIL) posts Q1 2026 results and advances HBV and DMD gene editing - Stock Titan
DTIL: Advanced gene editing trials and improved financials, with strong cash runway through 2028 - TradingView
Precision BioSciences: Q1 Earnings Snapshot - marketscreener.com
BRIEF-Precision BioSciences, Inc. Q1 Revenue USD 10.838 Million Vs. IBES Estimate USD 4.05 Million - TradingView
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Precision BioSciences (DTIL) Set to Report Q1 2026 Earnings with Analyst Expectations - GuruFocus
Precision BioSciences (DTIL) Projected to Post Earnings on Tuesday - MarketBeat
Precision BioSciences Inc expected to post a loss of 65 cents a shareEarnings Preview - TradingView
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 - BioSpace
Press Release: Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026 - Moomoo
H.C. Wainwright Reaffirms Their Buy Rating on Precision BioSciences (DTIL) - The Globe and Mail
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study - BioSpace
Precision BioSciences (DTIL) Launches First Clinical Trial for P - GuruFocus
Precision BioSciences opens enrollment for DMD gene therapy trial By Investing.com - Investing.com South Africa
Precision BioSciences opens enrollment for DMD gene therapy trial - Investing.com
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):